SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Breast Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned North American and European breast cancer thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. They address the following questions:
-- Has Novartis jumped ahead of Amgen in developing a breast cancer drug that provides a mortality benefit and preserves bone? MedPredict's panel debates the implications of Novartis' positive zoledronic acid (Zometa) data presented at ASCO 2008.
-- How prevalent is osteonecrosis of the jaw with antiresorptives, and how will this affect their usage in breast cancer?
-- How is triple negative breast cancer being treated, and where are the opportunities for development in this subtype?
-- What are the best approaches for development of inhibitors of mTOR, IGF1R, EGFR, PARP-1, HSP90, Src, angiogenesis, FA2, hedgehog, and vaccines?
"This report will provide essential strategic insight for those involved in development of breast cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our report discusses ongoing clinical programs, and offers insight into which of the many new drugs in development are likely to be significant improvements over current options."
Companies included in this report: Abbott (ABT-888, ABT-999, A-928605),
Abraxis/AstraZeneca (Abraxane), Amgen (denosumab, AMG-479), AstraZeneca
(Arimidex, olaparib, saracatinib), Bayer-Schering (Bonefos), BiPar
(BSI-201, BSI-401), Boehringer Ingelheim (Tovok), Bristol-Myers Squibb
(brivanib, BMS-754807, Sprycel, Ixempra), BMS/Imclone (Erbitux), Exelixis
(XL-765, XL-647), Genentech (Avastin, GDC-0941, Herceptin
Copyright©2008 PR Newswire.
All rights reserved